Product Images Belbuca

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Belbuca NDC 55700-867 by Quality Care Products, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - CamScanner 07 09 2020 10.09.51 1

image description - CamScanner 07 09 2020 10.09.51 1

This is a warning label regarding the use of Belbuca, a type of Buprenorphine Buccal Film, that is distributed by Zutlely. Belbuca may be habit forming and it is important to keep the product out of children's reach. The product comes in pouches with each pouch containing one Buccal film. Each Buccal film consists of 450 mcg Buprenorphine, equivalent to 485.1 mcg Buprenorphine Hydrochloride. The product is manufactured by BioDelivery Sciences International, Inc., located in Raleigh, NC. The lot number and expiration date are not available from the provided text.*

Chemical Structure - belbuca 01

Chemical Structure - belbuca 01

HCl is the chemical formula for hydrochloric acid, a strong acid commonly used in various industrial and laboratory processes. It is a colorless, highly corrosive solution with a pungent odor, and can cause severe skin and eye irritation upon contact. HCl is often used in the production of organic and inorganic compounds, as well as in the processing of metals and other materials.*

Figure 1 - belbuca 02

Figure 1 - belbuca 02

This is a graph showing the Cumulative Percentage of Patients with Response, with Belbuca and Placebo as the treatment options. The x-axis is labeled with percentage improvement in pain intensity from Titration to Week 12, while the y-axis is labeled with the cumulative percentage of patients with response.*

Figure 2 - belbuca 03

Figure 2 - belbuca 03

This is a chart that shows the cumulative percentage of patients with a response to BELBUCA and Placebo. The x-axis shows percentage improvement in pain intensity from Titration to Week 12. The y-axis shows the cumulative percentage of patients with a response.*

Figure A - belbuca 04

Figure A - belbuca 04

Figure B - belbuca 05

Figure B - belbuca 05

Figure C - belbuca 06

Figure C - belbuca 06

Figure D - belbuca 07

Figure D - belbuca 07

Figure E - belbuca 08

Figure E - belbuca 08

Figure F - belbuca 09

Figure F - belbuca 09

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.